| Year |
Citation |
Score |
| 2021 |
Lee L, Hizukuri Y, Severson P, Powell B, Zhang C, Ma Y, Narahara M, Sumi H, Hernandez D, Rajkhowa T, Bollag G, Levis M. A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia. Haematologica. PMID 33504139 DOI: 10.1182/Blood-2019-124030 |
0.339 |
|
| 2020 |
Severson P, West BL, Tap WD, Wainberg ZA, Tong-Starksen S, Hsu HH, Zhang C. Abstract 2020: Identification of abnormal CSF1 transcripts in tenosynovial giant cell tumors and dose-dependent increase in plasma CSF1 levels in response to pexidartinib treatment Clinical Trials. 80: 2020-2020. DOI: 10.1158/1538-7445.Am2020-2020 |
0.336 |
|
| 2018 |
Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, ... ... Severson P, et al. BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor. Cancer Discovery. PMID 29386193 DOI: 10.1158/2159-8290.Cd-17-0902 |
0.36 |
|
| 2016 |
Lin J, Zhang Y, Matusow B, Mumy A, Tsang G, Zhang J, Powers H, Spevak W, Severson P, Tsai J, Bollag G, Zhang C. A Mixed Type 1 and Type 2 Kinase Inhibitor That Overrides FLT3 F691 and D835 Resistance Mutations Blood. 128: 1074-1074. DOI: 10.1182/Blood.V128.22.1074.1074 |
0.325 |
|
| 2015 |
Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, ... ... Severson P, et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. The New England Journal of Medicine. 373: 428-37. PMID 26222558 DOI: 10.1056/Nejmoa1411366 |
0.317 |
|
| 2014 |
Severson PL, Vrba L, Stampfer MR, Futscher BW. Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutation Research. Genetic Toxicology and Environmental Mutagenesis. 775: 48-54. PMID 25435355 DOI: 10.1016/J.Mrgentox.2014.10.011 |
0.566 |
|
| 2014 |
Vorrink SU, Severson PL, Kulak MV, Futscher BW, Domann FE. Hypoxia perturbs aryl hydrocarbon receptor signaling and CYP1A1 expression induced by PCB 126 in human skin and liver-derived cell lines. Toxicology and Applied Pharmacology. 274: 408-16. PMID 24355420 DOI: 10.1016/J.Taap.2013.12.002 |
0.587 |
|
| 2014 |
Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Digestive Diseases and Sciences. 59: 365-74. PMID 24048683 DOI: 10.1007/S10620-013-2873-9 |
0.509 |
|
| 2013 |
Severson PL, Tokar EJ, Vrba L, Waalkes MP, Futscher BW. Coordinate H3K9 and DNA methylation silencing of ZNFs in toxicant-induced malignant transformation. Epigenetics. 8: 1080-8. PMID 23974009 DOI: 10.4161/Epi.25926 |
0.61 |
|
| 2013 |
Zhao F, Severson P, Pacheco S, Futscher BW, Klimecki WT. Arsenic exposure induces the Warburg effect in cultured human cells. Toxicology and Applied Pharmacology. 271: 72-7. PMID 23648393 DOI: 10.1016/J.Taap.2013.04.020 |
0.605 |
|
| 2012 |
Severson PL, Tokar EJ, Vrba L, Waalkes MP, Futscher BW. Agglomerates of aberrant DNA methylation are associated with toxicant-induced malignant transformation. Epigenetics. 7: 1238-48. PMID 22976526 DOI: 10.4161/Epi.22163 |
0.619 |
|
| 2012 |
Severson PL, Tokar EJ, Vrba L, Waalkes MP, Futscher BW. Abstract 5448: Common targets of epigenetic dysfunction in distinct target tissues of arsenic and cadmium induced malignant transformation Cancer Research. 72: 5448-5448. DOI: 10.1158/1538-7445.Am2012-5448 |
0.636 |
|
| 2010 |
Wnek SM, Jensen TJ, Severson PL, Futscher BW, Gandolfi AJ. Monomethylarsonous acid produces irreversible events resulting in malignant transformation of a human bladder cell line following 12 weeks of low-level exposure. Toxicological Sciences : An Official Journal of the Society of Toxicology. 116: 44-57. PMID 20375083 DOI: 10.1093/Toxsci/Kfq106 |
0.615 |
|
| 2009 |
Scholl J, Vollmer D, Bearss J, Jones C, McCarthy V, Severson P, Redkar S, Joshi‐Hangal R, Inloes R, Shi C, Bearss D. Abstract A190: In vivo activity of SGI‐110, a novel hypomethylating agent for treatment in hematology and solid malignancies Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A190 |
0.321 |
|
| 2008 |
Ahmed KBR, Nussenzveig RH, Chen AT, Prchal JT, Parker CJ, Gourley E, Severson P, Bearss J, Jones C, Warner SL, Vollmer D, Bearss DJ. Preclinical Characterization of the JAK-2 Inhibitor, SGI-1252 Blood. 112: 2629-2629. DOI: 10.1182/Blood.V112.11.2629.2629 |
0.319 |
|
| Show low-probability matches. |